Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease

Yanwei Zhang1,3,4, Caihong Liu1,4, Jing Liu1, Rui Guo1, Zheyi Yan1,3, Wenxia Liu1, Wayne Bond Lau2, Xiangying Jiao1, Jimin Cao1, Kun Xu3, Yongping Jia3, Xinliang Ma2 & Yajing Wang2*

The C1q complement/TNF-related protein superfamily (CTRPs) displays differential effects on the regulation of metabolic homeostasis, governing cardiovascular function. However, whether and how they may serve as predictor/pro-diagnosis factors for assessing the risks of coronary artery disease (CAD) remains controversial. Therefore, we performed a clinical study to elaborate on the implication of CTRPs (CTRP1, CTRP5, CTRP7, and CTRP15) in CAD. CTRP1 were significantly increased, whereas CTRP7 and CTRP15 levels were decreased in CAD patients compared to the non-CAD group. Significant differences in CTRP1 levels were discovered between the single- and triple-vascular-vessel lesion groups. ROC analysis revealed that CTRP7 and CTRP15 may serve as CAD markers, while CTRP1 may serve as a marker for the single-vessel lesion of CAD. CTRP1 and CTRP5 can serve as markers for the triple-vessel lesion. CTRP1 may serve as an independent risk predictor for triple-vessel lesion, whereas CTRP15 alteration may serve for a single-vessel lesion of CAD. CTRP1 may serve as a novel superior biomarker for diagnosis of severity of vessel-lesion of CAD patients. CTRP7, CTRP15 may serve as more suitable biomarker for the diagnosis of CAD patients, whereas CTRP5 may serve as an independent predictor for CAD. These findings suggest CTRPs may be the superior predictive factors for the vascular lesion of CAD and represent novel therapeutic targets against CAD.

Coronary artery disease (CAD) is one of the major cardiovascular diseases, which has a serious impact on human health1. CAD is a group of diseases including myocardial infarction, sudden angina pectoris, unstable angina pectoris, myocardial infarction, and sudden coronary death2. Multiple risk factors for CAD have been identified, which are highly associated with metabolism influencer/regulators including obesity, hypertension, dyslipidemia, diabetes, smoking, gender, age, etc.3. However, the sensitivity of the indicators limits the prediction and prognosis of CAD. Identification of new marker or indicator is in great need.

Previous studies suggest that adipokines, well-defined adipocyte endocrine factors, are important determinants for cardiovascular disorders with or without diabetes. Previous investigations implicate adiponectin (APN)'s circulationary level is negatively associated with patients who suffered coronary artery disease and4. CTRP (C1q complement/TNF-related protein) as a newly discovered family have shown diversity and wide distribution. Some of CTRP family members have similar metabolic effects with that of adiponectin, whereas others exert opposite effect as that adiponectin. Although emerging evidence suggests that CTRPs may serve as indicators for metabolic disorders, whether and how CTRPs may display its own unique potential relationship in predicting disease, especially cardiovascular disorders, is largely under-investigated.

CTRP family contains 15 family members (CTRP1 to CTRP15). Their functions display the differences and are highly related to their distributions5. Of all CTRPs identified to date, CTRP1, CTRP3, CTRP5, CTRP9, CTRP12, CTRP7, and CTRP13 have been reported to exhibit metabolic regulation and cardiovascular effects in animal models6-8. CTRP7 circulating levels are reduced in diet-induced diabetic or obese5,9, and CTRP7 deletion attenuates obesity-linked glucose intolerance, adipose tissue inflammation, and hepatic stress10. CTRP15 is a newly discovered actin that binds skeletal muscle and lipids in response to changes in energy status and predicts changes in metabolic circuits11. However, few CTRP members have been investigated in human studies and

1Department of Physiology, Shanxi Medical University, Shanxi, China. 2Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA. 3Department of Cardiology, The First Affiliated Hospital of Shanxi Medical University, Shanxi, China. 4These authors contribute equally: Yanwei Zhang and Caihong Liu. *email: yajing.wang@jefferson.edu
results are often controversial. For instance, one study reported that CTRP1 may slow the pathogenesis of early atherosclerosis and prevent the development of pathological blood vessels. However, another study demonstrated that CTRP1 level is associated with coronary artery disease. CTRP5 level is related to drug-eluting stent implantation after stent restenosis. However, the pathogenic or diagnostic role of CTRP5 in coronary diseases remain unclear in CAD patients.

Although above results suggest that CTRPs are associated with metabolism syndromes and play important role in the regulating cellular metabolism, unclear relationship between circulating CTRPs and coronary artery disease in clinic patients, complexity of CTRP family, and unclear interrelationship between members of CTRP family with different biological function, limited the CTRPs's clinical application both in therapeutic strategy exploration and as prognostic biomarkers. Therefore, we initiated a clinic investigation on plasma concentrations of CTRP1, CTRP5, CTRP7, and CTRP15, aiming to identify high potential markers to guidance new therapeutic strategy specifically in coronary artery disease, and to predict the severity of CAD. Additionally, the interrelation-of CTRPs levels in different vessel-lesions. Along with increased vascular lesions, CTRP1 and CTRP7 levels increased with the numbers of vessel-lesions in CAD patients (P < 0.05). CTRP5 showed increase tendency in age-matched groups. Notably, CTRP15 levels were decreased in CAD patients, and CTRP15 levels were lower in single-vessel and double-vessel as primary lesion and compared with triple-vessel lesion. Both models support

### Table 1. Clinical characteristics of participants in CAD and non-CAD groups. **p < 0.01 Comparison with non-CAD control subjects, a, p < 0.05 Comparison between single-vessel and triple-vessel.

| Variable                | Non-CAD | CAD         | Single-vessel-Lesion | Double-vessel-Lesion | Triple-vessel-Lesion | P       |
|-------------------------|---------|-------------|----------------------|----------------------|----------------------|---------|
| Age (year)              | 34.80 ± 9.73 | 54.90 ± 8.29 | 61.13 ± 9.06 | 63.63 ± 10.61 | 64.05 ± 8.74 | < 0.001 |
| Occlusion (N/Y)         | 40/0    | 30/0        | 36/4                | 36/4                | 30/10               | < 0.001 |
| Hypertension (N/Y)      | 40/0    | 30/0        | 24/16               | 25/15               | 19/21               | < 0.001 |
| Diabetes (N/Y)          | 40/0    | 30/0        | 31/9                | 32/8                | 28/12               | < 0.001 |
| Smoker (N/Y)            | 40/0    | 27/3        | 33/7                | 36/4                | 34/6                | 0.106   |
| TCH (mmol/L)            | 4.49 ± 0.92 | 4.67 ± 1.15 | 4.00 ± 1.06 | 4.07 ± 1.20 | 4.23 ± 1.21 | 0.030   |
| Triglyceride (mmol/L)   | 1.03 ± 0.58 | 1.66 ± 0.62 | 1.65 ± 1.12 | 1.70 ± 0.82 | 2.17 ± 2.08 | < 0.001 |
| HDL-cholesterol (mmol/L)| 1.43 ± 0.36 | 1.02 ± 0.15 | 0.98 ± 0.24 | 0.92 ± 0.18 | 1.11 ± 0.76 | < 0.001 |
| LDL-cholesterol (mmol/L)| 2.20 ± 0.62 | 2.87 ± 0.88 | 2.29 ± 0.84 | 2.37 ± 0.96 | 3.02 ± 2.50 | < 0.001 |
| ALT(U/L)                | 20.80 ± 23.66 | 24.10 ± 15.00 | 28.96 ± 16.11 | 35.50 ± 37.08 | 40.96 ± 61.58 | < 0.001 |
| AST(U/L)                | 27.87 ± 33.10 | 21.77 ± 6.48 | 27.61 ± 13.88 | 33.58 ± 28.96 | 38.93 ± 51.47 | 0.025   |
| EF(%)                   | 63.34 ± 8.72 | 62.27 ± 9.71 | 60.58 ± 8.91 | 60.03 ± 7.45 | 59.28 ± 9.11 | 0.197   |

### Table 2. Circulating levels of CTRPs of participants in CAD and non-CAD groups. **p < 0.01 Comparison with non-CAD control subjects, a, p < 0.05 Comparison between single-vessel and triple-vessel.

| Variable         | Non-CAD | CAD         | Single-vessel-Lesion | Double-vessel-Lesion | Triple-vessel-Lesion | P       |
|------------------|---------|-------------|----------------------|----------------------|----------------------|---------|
| CTRP1 (ng/ml)    | 5.28 ± 3.52 | 6.69 ± 5.36 | 6.32 ± 6.22 | 8.25 ± 9.26 | 11.31 ± 9.94a** | 0.019   |
| CTRP5 (ng/ml)    | 8.95 ± 3.18 | 9.82 ± 4.23 | 14.69 ± 14.36 | 10.75 ± 4.71 | 10.26 ± 10.00 | 0.080   |
| CTRP7 (ng/ml)    | 44.81 ± 41.02 | 20.83 ± 23.72** | 29.70 ± 51.53** | 34.83 ± 53.62** | 38.21 ± 78.17** | 0.005   |
| CTRP15 (ng/ml)   | 50.21 ± 34.79 | 40.40 ± 42.08* | 40.40 ± 38.18* | 26.82 ± 31.85*** | 27.29 ± 29.48*** | < 0.001 |

**Results**

**Subjects characteristics.** A total of 190 subjects were enrolled in this study. All the demographic data, baseline clinical and biochemical characteristics of the study subjects were summarized in Tables 1 and 2. Statistical analysis showed that CAD patients had markedly higher levels of vascular occlusion, hypertension, diabetes, total cholesterol (TCH), Triglyceride (TG), high density lipoprotein (HDL)-cholesterol, low density lipoprotein (LDL)-cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Interesting, circulating CTRP1 was significantly high in CAD patients, while CTRP7 and CTRP15 were decreased compared to non-CAD participants (Table 2, p < 0.01). In addition, CTRP7 and CTRP15 levels were reduced in elder non-CAD when compared with young non-CAD controls (Table 2).

To reveal the relationship between CTRPs and vascular lesions and the severity of lesion stages, we evaluated CTRPs levels in different vessel-lesions. Along with increased vascular lesions, CTRP1 and CTRP7 levels increased with the numbers of vessel-lesions in CAD patients (P < 0.05). CTRP5 showed increase tendency in age-matched groups. Notably, CTRP15 levels were decreased in CAD patients, and CTRP15 levels were lower in multiple vessel-lesion group than that in the single-vessel-lesion group. Furthermore, we constructed two models for multivariate regression analysis to assess the independent determinants for severity of diseased coronary vessels. In model 1, we included all risk factors and compared multiple vessel lesions (combining double-vessel and triple-vessel lesion together) to single-vessel lesion. In model 2, we additionally adjusted the analysis by grouping single-vessel and double-vessel as primary lesion and compared with triple-vessel lesion. Both models support...
that CTRP1 is associated with the severity of vessel-lesion of CAD (Tables 3 and 4). CTRP5 may serve as an independent predictor for CAD.

To further clarify the relationship between CTRPs and CAD, we performed a serial analysis. First, as illustrated in Table 5, we build a multivariate model among the significant variables noted by univariate analysis to determine potential screening markers for CAD. Results showed that CAD is highly correlated with Sex, age, diabetes and AST (p < 0.05). CTRP5 was an independent predictor for CAD (Table 5). Meanwhile, Sex, age, diabetes, smoking, TCH, TG, HDL-C, ALT, CTRP1 and CTRP15 were significantly positively associated with CAD (Table 6). Logistic regression analysis as shown in Table 7 and 8 indicated that reduced CTRP15 was a high-risk factor for a single-vessel lesion in CAD whereas increased CTRP1, occlusion and smoking were the high-risk factors for triple-vessel lesions of CAD.

To assess whether CTRPs can serve as a marker for CAD, a receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic value of CTRPs for CAD. As illustrated in Fig. 1, the AUC (area under the curve) was 0.626 for CTRP7 (P < 0.01, Fig. 1A, n = 120) and 0.665 for CTRP15 (p = 0.001, Fig. 1B, n = 120), confirming specificity and sensitivity of CTRP7 and CTRP15 as biomarkers for CAD. The ROC analysis results of CTRP5 and CTRP1 showed the AUC was 0.529 and 0.554 respectively, failed to serve as biomarkers for CAD as a whole. Notably, the AUC of CTRP1 was 0.613 (95% confidence interval 0.509–0.718, P = 0.044) for single-vessel lesions (Fig. 2A), and AUC was 0.650 (p = 0.007) for triple-vessel (Fig. 2B). Furthermore, the AUC of CTRP1 for multiple-vessel lesions was 0.613 (p = 0.045) (Fig. 2C), hence, CTRP1 value was the optimistic selected models for prognosticating vessel-lesions in CAD. Although the AUC of CTRP5 for triple-vessel lesions was 0.642 (p = 0.011), the signal-vessel lesion and multiple-vessel lesion failed to serve as a marker (Fig. 3). Taken together, these results suggest that CTRP7 and CTRP15 may serve as biomarkers for CAD as whole while CTRP1 may serve as a marker for severity of vessel-lesions.

To identify the etiology of altered CTRPs in CAD patients, we examined whether CTRPs is associated with other risk factors. Multiple linear regression was used to determine the relationship of CTRPs with other risk factors. As shown in Tables 9 and 10, the results revealed that CTRP5 and CTRP7 were not associated with any other variables. However, serum CTRP1 was positively associated with age and vascular occlusion. When

| Variable     | OR  | OR CI95% | P    |
|--------------|-----|----------|------|
| CTRP1(ng/ml) | 1.049* | 1.002–1.097 | 0.039 |
| Sex(M/F)     | 1.289 | 0.461–3.599 | 0.628 |
| Age(year)    | 0.998 | 0.952–1.046 | 0.934 |
| Hypertension(N/Y) | 1.884 | 0.816–4.347 | 0.138 |
| HDL-C(mmol/L) | 2.060 | 0.716–5.930 | 0.180 |
| TCH(mmol/L)  | 1.152 | 0.813–1.632 | 0.426 |
| Smoker(N/Y)  | 0.755 | 0.217–2.621 | 0.658 |

Table 3. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression analysis). Comparison single-vessel with double-vessel and triple-vessel lesion.

| Variable     | OR  | OR CI95% | P    |
|--------------|-----|----------|------|
| CTRP1(ng/ml) | 1.066* | 1.004–1.132 | 0.037 |
| Sex(M/F)     | 0.384 | 0.132–1.119 | 0.079 |
| Age(year)    | 1.041 | 0.992–1.092 | 0.106 |
| Hypertension(N/Y) | 1.016 | 0.441–2.343 | 0.970 |
| HDL-C(mmol/L) | 1.180 | 0.477–2.919 | 0.728 |
| TCH(mmol/L)  | 1.151 | 0.802–1.650 | 0.446 |
| Smoker(N/Y)  | 0.362 | 0.107–1.226 | 0.102 |

Table 4. Correlation between CTRP1 and number of diseased coronary vessels (multivariate regression analysis). Comparison single-vessel and double-vessel with triple-vessel lesion.

| Variable | OR  | OR CI95% | P    |
|----------|-----|----------|------|
| Sex      | 8.92** | 1.91–41.76 | 0.005 |
| Age      | 0.82*** | 0.74–0.89 | <0.001 |
| Diabetes | 207.82** | 5.53–7811.55 | 0.004 |
| CTRP5    | 1.17* | 0.73–0.99 | 0.038 |
| AST      | 0.96* | 0.93–0.99 | 0.029 |

Table 5. Correlation between CAD and CTRPs (multivariate regression analysis). *p < 0.05. **p < 0.01. ***p < 0.001.
other variables remain the same, CTRP1 increases by 0.088 ng/ml for each additional year of age (Table 9). Meanwhile, there was no evidence revealing the positive interrelationship among the CTRP family members in CAD population.

In contrast, age, diabetes, and TCH had a significant association with CTRP15. Serum CTRP15 was inversely correlated with age and diabetes, but TG was positively correlated with CTRP15. In order to further determine the relationship between CTRPs and severity of vessel-lesions in coronary artery disease, we have studied the correlation between the number of lesions in CAD and clinical indicators. The results showed that CTRP1 level is positively correlated with AST in single-vessel disease (Table 11). CTRP15 and diabetes were negatively correlated with the three-vessel disease (Table 12).

**Discussion**

We reported a discovery of new biomarkers for coronary artery disease. The current study demonstrated that CTRP7 and CTRP15 may serve novel biomarkers of CAD, and CTRP1 may predict the vessel-lesion severity in CAD. Moreover, CTRP5 may serve an independent predictor for CAD. In addition, compared with the control group, concentrations of both CTRP5 and CTRP7 were significantly decreased in CAD patients while CTRP1 concentrations were elevated.

In recent years, there have been many studies investigating serum levels of CTRP1 and coronary artery disease. Studies have shown that CTRP1 is a marker of human atherosclerosis and promotes atherosclerosis in...
disease and in patients with coronary in-stent restenosis since serum CTRP5 levels are significantly elevated. This is inconsistent with previous reports by other groups. Small patients’ populations and limited race (Chinese Han population) could be the reason to cause this discrepancy. However, it acts as a biomarker for the increased vessel-lesion level. The increased level of CTRP1 in circulation may be attributed to disturbed flow and other risk factors-induced inflammatory cytokines. To further explore the risk factor for elevated CTRP1 and elaborate the relationship between clinical indicators and CTRP1, we applied multiple linear regression analysis. The results indicated that plasma CTRP1 levels were positively correlated with age and vascular occlusion. Furthermore, CTRP1 was positively correlated with AST in single-vessel disease. Despite the advantageous findings of our study regarding the role of CTRP1 in CAD-related vessel lesion, we recognize some limitations. We did not investigate other vascular disease relationship with CTRP1 and other possible pathogenic molecules including other CTRP family members. It is highly desirable to conduct additional studies regarding CTRP1 role in pathogenesis of CAD with larger samples of patients utilizing prospective designs.

CTRP5 is wildly expressed in various cells, with the highest expression level in adipose tissue. It inhibits adiponectin and resistin release in a dose-dependent manner. Simultaneously, CTRP5 can promote transcytosis and oxidative modification of low-density lipoprotein and accelerate atherosclerosis development. Studies have shown that CTRP5 can be used as a biomarker for potential new inflammatory chronic obstructive pulmonary disease and in patients with coronary in-stent restenosis since serum CTRP5 levels are significantly elevated. However, there are few studies investigating the relationship between CTRP5 and coronary artery disease. In our study, we divided the recruited patient’s population into two groups (elder and young) in the normal physical examination group. Three stages of vessel-lesion in diagnosed as coronary artery disease group and the CTRP5 levels were compared among the groups. The results showed no differences within the non-CAD group in different age. However, CTRP5 level was increased in CAD group when compared with non-CAD. Notably, the concentration of serum CTRP5 showed an increasing tendency in a single-vessel lesion group than the three-vessel lesion group. The small sample size and the controversial deleterious effect of CTRP5 in the vascular system may contribute to the unparalleled phenomenon between CTRP5 and the level of vessel lesions.

Although circulating CTRP7 level has been reported to be elevated in obese people, and CTRP7 knockout mice exhibit elevated glucose metabolism, decreased adipose tissue inflammation, liver fibrosis, cellular oxidation, and endoplasmic reticulum stress in, the CTRP7 circulating levels and coronary artery disease is largely unknown. Studies have shown that circulating CTRP15 concentration and its gene expression are affected by metabolism. CTRP15 may potentially be used as a circulating biomarker for predicting cardiovascular disease (CVD) risk in obese and T2DM patients. In our study, serum CTRP7 and CTRP15 levels in CAD were reduced compared with the non-CAD group. CTRP7 and CTRP15 are novel identified diagnostic biomarker for CAD, while CTRP1 and CTRP5 fail in this study. These results suggest that CTRP7 and CTRP15 presents more sensitivity and stability as biomarkers than the other two. Meanwhile, the result showed that CTRP15 was negatively correlated with age and diabetes in coronary artery disease patients; and it is positively correlated with TG levels. Further analysis revealed that the negative correlation between CTRP15 and diabetes is significant in the three-vessel lesion of CAD.

We further carried out multiple regression analysis and found that CTRP5 can be an independent indicator for CAD, but it failed to predict the severity of vessel-lesion, and CTRP5 might be a possible therapeutic target in...
prevention or ameliorating CAD in future study. In addition, consistent with other studies, gender, age, diabetes, and AST are all risk factors for CAD.

Our research has some limitations. The first is relatively small sample size and is Chinese Han population only. Secondly, our survey was a case-controlled study by which it cannot determine the incident rate of disease in exposed and non-exposed groups. Thirdly, we utilized AUC > 0.6 as cutoff for the resultant logistic-regression based ROC analyses. However, CTRPs are not pre-existing risk model in CAD and our study was restricted to a small study size. This factors AUC has value for evaluating CAD risks even with a cutoff value of 0.6. Fourthly, mechanisms causing circulating CTRPs level alteration need to be further explored. Our preliminary experiments suggest that unbalanced miRNA pool produced by dysfunctional adipocytes may initiate pathological long-distance communication between adipocytes and cardiomyocytes, causing CTRPs level alteration, abnormal CTRP9 assembling and expression. Finally yet importantly, we needed additional in vivo animal studies to elucidate the physiology and mechanism of action of CTRP in the development of CAD.

In conclusion, we have demonstrated that circulating CTRP1 can predict the severity of vessel-lesions in coronary artery disease, and CTRP7 and CTRP15 can serve as new CAD diagnostic biomarker. In addition, our study showed that CTRP15 is inversely associated with diabetes in three-vessel coronary artery disease. CTRP5 is the independent risk for CAD. The new discovered CTRPs provide the future therapeutic target and pre-diagnostic biomarker for coronary artery disease.

| Variable     | AUC   | SE    | P-value | 95%CI  |
|--------------|-------|-------|---------|--------|
| CTRP7 (ng/ml)| 0.626 | 0.041 | 0.004   | 0.546-0.706 |
| CTRP15 (ng/ml)| 0.665 | 0.040 | <0.001  | 0.587-0.743 |
| CTRP1 (ng/ml)| 0.554 | 0.041 | 0.211   | 0.473-0.635 |
| CTRP5 (ng/ml)| 0.529 | 0.042 | 0.512   | 0.447-0.610 |

**Figure 1.** ROC curves for CAD diagnosis by CTRPs level. (A) ROC curves for CAD diagnosis by CTRP7 level. (B) ROC curve for CAD diagnosis by circulating CTRP15 level. (C) ROC curve for CAD diagnosis by CTRP5 level. (D) ROC curve for CAD diagnosis by CTRP1 level.
Methods

Participants and eligibility. The patients were enrolled in the first affiliated Hospital of Shanxi Medical University from January 2017 to September 2018. A total of 190 subjects attended. The research included 40 healthy control subjects, 30 patients without stenosis after coronary angiography, and 120 patients with coronary artery disease (40 patients with a single vessel, 40 patients with double-vessel and 40 patients with triple-vessel). All research protocols were approved by the Ethics Committee of Shanxi Medical University and performed in accordance with the latest version of the Declaration of Helsinki. Moreover, all patients and control subjects were given written informed consent. The diagnostic criteria of CAD were a 50% or greater organic stenosis of at least one main coronary artery as confirmed by coronary angiogram, two stenoses ≥50% was considered as a double-vessel disease, and more than two stenoses was defined as a triple-vessel disease. Exclusion criteria for this study were: old myocardial infarction, congestive heart failure, severe hepatic and renal dysfunction, malignancy, a history of trauma or surgery within one-month, valvular heart disease, pregnancy, or any factor affecting body weight such as hyperthyroidism, corticosteroids, or contraceptives, or acute and chronic infection.

Biochemical and hormonal analysis. The arterial blood extracted directly from the sheath of radial artery before coronary angiography was separated into the Eppendorf tube at 4°C for 20 minutes by 3000 rpm centrifugation, then frozen and stored at −80°C until determined. Total cholesterol(TC), triglycerides(TG), high-density
**Figure 3.** ROC curves for vessel-lesion of CAD diagnosis by CTRP5 level. (A) ROC curve for triple-vessel-lesion of CAD diagnosis by CTRP5 level. (B) ROC curve for multiple-vessel-lesion of CAD diagnosis by CTRP5 level.

| Variable          | β    | SE   | P    |
|-------------------|------|------|------|
| Sex(M/F)          | 0.984| 1.248| 0.431|
| Age(year)         | 0.088*| 0.042| 0.037|
| Occlusion(N/Y)    | 4.445*| 1.889| 0.020|
| Diabetes(N/Y)     | 0.733| 1.698| 0.666|
| TCH(mmol/L)       | −0.531| 0.546| 0.332|
| HDL-C(mmol/L)     | 1.253| 1.326| 0.346|
| Smoker(N/Y)       | 2.791| 1.903| 0.144|
| AST(U/L)          | 0.022| 0.017| 0.202|
| TG(mmol/L)        | 0.906| 0.506| 0.075|
| Hypertension(N/Y) | 0.033| 1.526| 0.983|

Table 9. Multiple linear regression analysis of CTRP1 and clinical indicators. *p < 0.05.

| Variable          | β    | SE   | P    |
|-------------------|------|------|------|
| Sex(M/F)          | 4.222| 5.832| 0.470|
| Age(year)         | −0.606**| 0.196| 0.002|
| Occlusion(N/Y)    | 2.675| 8.828| 0.762|
| Diabetes(N/Y)     | −19.379*| 7.935| 0.016|
| TCH(mmol/L)       | 6.162*| 2.553| 0.017|
| HDL-C(mmol/L)     | −5.271| 6.197| 0.396|
| Smoker(N/Y)       | 4.577| 8.893| 0.607|
| AST(U/L)          | −0.132| 0.081| 0.104|
| TG(mmol/L)        | −0.990| 2.365| 0.676|
| Hypertension(N/Y) | 11.924| 7.134| 0.096|

Table 10. Multiple linear regression analysis of CTRP15 and clinical indicators. *p < 0.05.
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, homocysteine (HCY) were determined by commercial kit via Hitachi 7600 biochemical automatic analyzer (Hitachi, Tokyo, Japan).

Echocardiographic examination. The echocardiographic measurements were carried out while the patients were in the left lateral decubitus with standard precordial positions by Philips Epiq 7C Cardiology Ultrasound machine (Los Angeles, CA, USA). The left ventricle ejection fraction (LV EF) was assessed with biplane method of disks (modified Simpson’s rule) according to the American Society of Echocardiography (ASE). LVEF = ([LV end-diastolic volume] - [LV end-systolic volume]) / ([LV end-diastolic volume]).

Measurement of plasma CTRP1, CTRP5, CTRP7 and CTRP15. Plasma CTRP1, CTRP5, CTRP7, and CTRP15 levels were measured by commercial enzyme-linked immunosorbent assay (ELISA) kit (Cat, SK00083-01 for CTRP1; Cat, SK00594-06 for CTRP5; Cat, SK00396-09 for CTRP7; SK00393-19 for CTRP15, Aviscera Bioscience, Santa Clara, CA) per manufacturer’s instructions. Intra- and inter-assay coefficients of variation (CV) for CTRP1, CTRP5, and CTRP15 were 6–8% and 8–12%, respectively, and intra- and inter-assay coefficients of variation for CTRP7 were 4–6% and 8–10%, respectively.

Statistical analysis. Descriptive analysis was applied, and quantitative data were conducted by the Shapiro-Wilk test for normality. Continuous variables are expressed as mean ± standard error (SE). Data (Sex, Smoker, Diabetes) that did not conform to normality distribution were expressed as median ± interquartile (IQR).

We first examined differences between groups of the phenotypes of interest in the control, single-vessel-lesion, double-vessel-lesion, and triple-vessel-lesion by the Mann-Whitney U test to compare of continuous variables and the Chi-square test for statistical inference of categorical variables. To assess the effect of the subjects with different lesions, we applied a Chi-square test on different groups.

Next, we used logistic regression to estimate the association between CAD and case-control status of all other parameters as defined above. In addition to the use of multivariate regression for determining potential screening markers for CAD, we adjusted our model for other risk factors by univariate regression analysis and evaluated the collinearity diagnostics. The predicted probability of being diagnosed with CAD was used as a surrogate marker to construct receiver operating characteristic (ROC) curves. The area under the ROC curve (AUC) served as an accuracy index evaluating the diagnostic performance of the noted marker. We used multiple linear regression to describe the dependencies between CTRPs and multiple independent variables in CAD.

All statistical analyses were performed using SPSS 20.0 (Chicago, IL, USA). P-value less than 0.05 in a two-tailed test were considered statistically significant.

Received: 5 August 2019; Accepted: 26 December 2019; Published online: 21 January 2020

| Variable          | β   | SE  | P     |
|-------------------|-----|-----|-------|
| Sex(M/F)          | −0.705 | 2.685 | 0.795 |
| Age(year)         | 0.119 | 0.138 | 0.395 |
| Occlusion(N/Y)    | 0.406 | 3.626 | 0.912 |
| Diabetes(N/Y)     | 2.859 | 2.413 | 0.292 |
| TCH(mmol/L)       | −0.049 | 1.276 | 0.969 |
| HDL-C(mmol/L)     | 1.745 | 5.786 | 0.765 |
| Smoker(N/Y)       | 4.298 | 2.935 | 0.154 |
| AST(U/L)          | 0.168* | 0.079 | 0.044 |
| TG(mmol/L)        | 0.777 | 1.056 | 0.468 |
| Hypertension(N/Y) | 1.593 | 2.256 | 0.486 |

Table 11. Multiple linear regression analysis of CTRP1 and clinical indicators in single-vessel. *p < 0.05.

| Variable          | β   | SE  | P     |
|-------------------|-----|-----|-------|
| Sex(M/F)          | 12.408 | 13.942 | 0.381 |
| Age(year)         | −0.723 | 0.829 | 0.390 |
| Occlusion(N/Y)    | −3.458 | 13.430 | 0.799 |
| Diabetes(N/Y)     | −32.302* | 15.032 | 0.040 |
| TCH(mmol/L)       | 0.190 | 5.196 | 0.971 |
| HDL-C(mmol/L)     | −2.816 | 7.637 | 0.715 |
| Smoker(N/Y)       | 2.251 | 17.093 | 0.896 |
| AST(U/L)          | −0.092 | 0.128 | 0.478 |
| TG(mmol/L)        | 0.145 | 3.202 | 0.964 |
| Hypertension(N/Y) | 25.093 | 14.429 | 0.093 |

Table 12. Multiple linear regression analysis of CTRP15 and clinical indicators in triple-vessel.
References

1. Kaestori, C. M. et al. Comparative analysis of cardiovascular disease risk factors influencing nonfatal acute coronary syndrome and ischemic stroke. Am J Cardiol 112, 349–354, https://doi.org/10.1016/j.amjcard.2013.03.039 (2013).

2. Foley, J. R., Plein, S. & Greenwood, J. P. Assessment of stable coronary artery disease by cardiovascular magnetic resonance imaging: Current and emerging techniques. World J Cardiol 9, 92–108, https://doi.org/10.4330/wjc.v9.i12.92 (2017).

3. Yu, X. et al. Serum Triglyceride Lipase Concentrations are Independent Risk Factors for Coronary Artery Disease and In-Stent Restenosis. J Atheroscler Thromb 26, 762–774, https://doi.org/10.5551/jat.46821 (2019).

4. Ouchi, N. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103, 1057–1063 (2001).

5. Wang, Y.-J. et al. Adipose tissue-derived cytokines, CTRPs as biomarkers and therapeutic targets in metabolism and the cardiovascular system. Vessel Plus, https://doi.org/10.20517/2574-1209.2017.29 (2017).

6. Shibata, R., Ouchi, N., Ohashi, K. & Murohara, T. The role of adipokines in cardiovascular disease. J Cardiol 78, 329–334, https://doi.org/10.1016/j.jjcc.2017.02.006 (2017).

7. Sun, Y. et al. C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 128, S113–120, https://doi.org/10.1161/CIRCULATIONAHA.112.000100 (2013).

8. Yi, W. et al. C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 125, 3159–3169, https://doi.org/10.1161/CIRCULATIONAHA.112.099997 (2012).

9. Rohrbach, S., Aurich, A. C., Li, L. & Nienmann, B. Age-associated loss in adiponectin-activation by caloric restriction: lack of compensation by enhanced inducibility of adiponectin paralogs CTRP2 and CTRP7. Mol Cell Endocrinol 277, 26–34, https://doi.org/10.1016/j.mce.2007.07.005 (2007).

10. Petersen, P. S. et al. CTRP7 deletion attenuates obesity-linked glucose intolerance, adipose tissue inflammation, and hepatic stress. Am J Physiol Endocrinol Metab 312, E309–E325, https://doi.org/10.1152/ajpendo.00344.2016 (2017).

11. Seldin, M. M., Peterson, J. M., Byerly, M. S., Wei, Z. & Wong, G. W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem 287, 11968–11980, https://doi.org/10.1074/jbc.M111.336834 (2012).

12. Wang, X. et al. C1q/TNF-related protein 1 links macrophage adipose metabolism to inflammation and atherosclerosis. Atherosclerosis 250, 38–45, https://doi.org/10.1016/j.atherosclerosis.2016.04.024 (2016).

13. Yuasa, D. et al. Association of circulating C1q/TNF-related protein 1 levels with coronary artery disease in men. PLoS One 9, e99846, https://doi.org/10.1371/journal.pone.0099846 (2014).

14. Lasser, G. et al. C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood 117, 423–430, https://doi.org/10.1182/blood-2005-04-1425 (2006).

15. Zhang, C. L., Wu, L. L. & Li, L. Research progress of complement C1q/tumor necrosis factor-related protein 3. Sheng Li Xue Bao 69, 666–676 (2017).

16. Yang, W. M. & Lee, W. CTRP5 ameliorates palmitate-induced apoptosis and insulin resistance through activation of AMPK and fatty acid oxidation. Biochem Biophys Res Commun 452, 715–721, https://doi.org/10.1016/j.bbrc.2014.08.145 (2014).

17. Yang, Y. et al. Association Between C1q/TNF-Related Protein-1 Levels in Human Plasma and Epicardial Adipose Tissues and Congestive Heart Failure. Cell Physiol Biochem 42, 2130–2143, https://doi.org/10.1159/000479915 (2017).

18. Shen, L., Wang, S., Ling, Y. & Liang, W. Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease. J Med Monit 47, 2571–2579, https://doi.org/10.1177/0300056519847372 (2019).

19. Muendlein, A. et al. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. Atherosclerosis 236, 1–6, https://doi.org/10.1016/j.atherosclerosis.2019.04.222 (2019).

20. Liu, Z. H. et al. C1q/TNF-related protein 1 promotes endothelial barrier dysfunction under disturbed flow. Biochem Biophys Res Commun 490, 580–586, https://doi.org/10.1016/j.bbrc.2017.06.081 (2017).

21. Lu, L. et al. C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. Eur Heart J 37, 1762–1771, https://doi.org/10.1093/eurheartj/ehv649 (2016).

22. Schmid, A. et al. Regulation and function of C1q/TNF-related protein-5 (CTRP-5) in the context of adipocyte biology. Exp Clin Endocrinol Diabetes 121, 310–317, https://doi.org/10.1055/s-0035-1533299 (2013).

23. Li, C. et al. CTRP5 promotes transcytosis and oxidative modification of low-density lipoprotein and the development of atherosclerosis. Atherosclerosis 278, 197–209, https://doi.org/10.1016/j.atherosclerosis.2018.09.037 (2018).

24. Li, D. et al. Adipokine CTRP-5 as a Potential Novel Inflammatory Biomarker in Chronic Obstructive Pulmonary Disease. Medicine (Baltimore) 94, e1503, https://doi.org/10.1097/MD.0000000000001503 (2015).

25. Shen, Y. et al. Association of increased serum CTRPs levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells. Int J Cardiol 228, 129–136, https://doi.org/10.1016/j.ijca.2016.11.034 (2017).

26. Seldin, M. M. & Wong, G. W. Regulation of tissue crosstalk by skeletal muscle-derived myonectin and other myokines. Adipocyte 1, 200–202, https://doi.org/10.4161/adip.20877 (2012).

27. Mi, Q. et al. Circulating C1q/TNF-related protein isoform 15 is a marker for the presence of metabolic syndrome. Diabetes Metab Res Rev 35, e3085, https://doi.org/10.1002/dmrr.3085 (2019).

28. Duseja, A. et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 5, 51–68, https://doi.org/10.1016/j.jceh.2015.02.006 (2015).

Acknowledgements

This study was supported by the grants from Shanxi Key Subjects Construction (1331KSC), Innovative Talents of Higher Learning Institutions of Shanxi, American Diabetes Association 1-17-IBS-297, and Natural Science Foundation of China 81670278.

Author contributions

Y.W.Z. and C.H.L. participated in data collection, analysis, and interpretation of the results and writing the manuscript. J.L., R.G., Z.Y., Y.P.J., K.X. and W.L. contributed to data collection and interpretation of the results. W.B.L. and Y.J.W. contributed to the interpretation of the results and editing the manuscript. X.Y.J., J.M.C., X.L.M. and Y.J.W. conceived of the study as consultants. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.
Additional information

Correspondence and requests for materials should be addressed to Y.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020